Difficulty in achieving therapeutic serum concentrations of salicylate in Kawasaki disease

Area of Science:

• Pediatric Pharmacology
• Rheumatology
• Clinical Toxicology

Background:

• Kawasaki disease requires effective anti-inflammatory treatment.
• Acetylsalicylic acid (ASA) is commonly used, but optimal dosing and absorption in children are not fully understood.
• Variability in salicylate pharmacokinetics can impact treatment efficacy and safety.

Purpose of the Study:

• To investigate the correlation between acetylsalicylic acid (ASA) dosage and serum salicylate concentrations in children with Kawasaki disease.
• To assess the absorption and clearance of ASA in this patient population.
• To determine the optimal dosing strategy for achieving therapeutic salicylate levels while minimizing toxicity.

Main Methods:

• Retrospective analysis of 49 children with Kawasaki disease treated with ASA (30-180 mg/kg).
• Prospective study of 4 additional children to evaluate ASA absorption and renal clearance.
• Measurement of serum salicylate concentrations and assessment of adverse events like gastritis.

Main Results:

• Good correlation between ASA dose and serum salicylate levels (r=0.69), but with significant variability.
• Doses <80 mg/kg/day consistently resulted in subtherapeutic levels (<20 mg/dl).
• Doses >120 mg/kg/day showed 28% toxic levels (>30 mg/dl) and aspirin-induced gastritis in 3 children.
• Impaired ASA absorption (14-60%) and reduced renal clearance were observed, leading to subtherapeutic steady-state concentrations (7-11.5 mg/dl).

Conclusions:

• High-dose ASA therapy for Kawasaki disease exhibits unpredictable absorption and wide variability in serum concentrations.
• Dosing requires careful titration and frequent therapeutic drug monitoring to balance efficacy and toxicity.
• Impaired absorption necessitates higher doses, increasing the risk of gastritis and toxic levels.